Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate

Hosking, David, Lyles, Kenneth, Brown, Jacques P, Fraser, William D, Miller, Paul, Curiel, Manuel Diaz, Devogelaer, Jean-Pierre, Hooper, Michael, Su, Guoqin, Zelenakas, Ken, Pak, Judy, Fashola, Taiwo, Saidi, Youssef, Eriksen, Erik Fink and Reid, Ian R (2007) Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. Journal of Bone and Mineral Research, 22 (1). pp. 142-148. ISSN 1523-4681

Full text not available from this repository. (Request a copy)

Abstract

A single 5-mg infusion of zoledronic acid restores biochemical markers of bone turnover into the reference range in the majority of patients with Paget's disease and maintains biochemical remission for at least 2 years. This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy.

Item Type:	Article
Uncontrolled Keywords:	administration, oral,aged,aged, 80 and over,alkaline phosphatase,bone density conservation agents,bone and bones,diphosphonates,etidronic acid,follow-up studies,humans,imidazoles,infusions, intravenous,osteitis deformans
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School Faculty of Arts and Humanities > School of American Studies (former - to 2014)
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Musculoskeletal Medicine Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Depositing User:	Rhiannon Harvey
Date Deposited:	08 Jun 2011 13:05
Last Modified:	19 Oct 2023 00:50
URI:	https://ueaeprints.uea.ac.uk/id/eprint/32062
DOI:	10.1359/jbmr.061001

Actions (login required)

View Item